Kendle Appoints Jeffrey M. Zucker to Lead Global Patient Recruitment Efforts
CINCINNATI, Aug. 23 Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization, today announced the appointment of Jeffrey M. Zucker as Senior Director and Global Head, Patient Recruitment. Zucker will provide global leadership for the development and implementation of innovative strategies to accelerate patient recruitment, improve retention and support the timely and efficient delivery of Phase I-IV clinical development programs for the Company's biopharmaceutical customers. He brings nearly 15 years of clinical development and management experience to Kendle.
"Patient recruitment is at the core of the clinical development process," said Stephen Cutler, PhD, Senior Vice President and Chief Operating Officer. "Finding the right patients for the right studies and keeping them engaged throughout is essential to producing sound clinical research. Jeff's extensive management experience across many facets of the biopharmaceutical industry will be a great asset for our customers and we are pleased to welcome him to Kendle."
Zucker brings extensive experience from across the biopharmaceutical industry, including management positions focused on site selection and patient recruitment. In his most recent position, he led global trial optimization efforts for Merck & Co. He also has served as Director of Inpatient Operations at CRI Worldwide and as founder and President of Applied Research Trials, a biopharmaceutical consulting firm focused on improving clinical research trials and processes. Zucker has held leadership positions for Eli Lilly, Princeton Biomedical Research and multiple clinical investigative sites. He holds a Master of Science in Group Process and Group Psychotherapy from Hahnemann University in Philadelphia and a Bachelor of Science in psychology from Pennsylvania State University.
Innovative patient recruitment strategies in support of investigative sites have earned Kendle consistent recognition as a CRO of choice. The Company is the only CRO to be ranked consistently among the top three CROs to work with in the 2010, 2009, 2008 and 2007 CenterWatch surveys of U.S. and European investigative sites.
Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing drugs to market for the benefit of patients worldwide. As one of the world's largest global providers of Phase I-IV services, we offer experience spanning more than 100 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges.
Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 500, Cincinnati, OH 45202 or from the Company's website at www.kendle.com.
SOURCE Kendle International Inc.
You May Also Like